Matches in SemOpenAlex for { <https://semopenalex.org/work/W2753018164> ?p ?o ?g. }
Showing items 1 to 73 of
73
with 100 items per page.
- W2753018164 abstract "MOPP/ABV hybrid chemotherapy was introduced in for front-line treatment of advanced Hodkgins disease (HD) to deliver the dose intensive treatment with acceptable tolerance. We report the results of a study designed to evaluate the efficacy, response predictors, toxicity predictors and overall tolerance of this combination chemotherapy in single institution. Sixty-one consecutive, newly diagnosed patients (51 with advanced HD and 10 with ALCL, 41% males, with median age of 32 years, stage I-II 47%, III-IV 53% were) treated in the period 1990-1996 with 6 cycles of MOPP/ABV hybrid chemotherapy. Median trial time was more then 25 months. Response was classified 1 month after completion of 6 cycles. Complete response was obtained in 51 patients (84%), partial response in 9 (15%) and non response in 1 (2%) of patients. Age, sex, stage, histology, presence of symptoms, ESR, E, Hb, Hct, Tr, Rtc, Fe, UIBC, Cu, L, Bil, SGOT, SGPT, AP, LDH, BM infiltration. ..failed to predict response. Only absolute lymphocyte count was associated with response at the significant level (p=0.0031), stage was borderline significant (p=0.054). Projected DFS at 8 years is 75%, overall survival at 8 years is 60%. Chemotherapy was delivered to the patients in more then 98% of theoretical dose intensity. No toxicity was observed in 49, grade I-II toxicity in 10 and III-IV in 2 patients. Only platelet count and bilirubin at diagnosis were found to be associated with dose reduction at the significant level. Overall tolerance was very good. Results are comparable to other series with HD. This treatment was also efficient in ALCL patients. In conclusion, MOPP/ABV hybrid chemotherapy is well tolerated and effective treatment for remission induction in advanced HD and ALCL." @default.
- W2753018164 created "2017-09-15" @default.
- W2753018164 creator A5021807188 @default.
- W2753018164 creator A5033103275 @default.
- W2753018164 creator A5035840054 @default.
- W2753018164 creator A5038299892 @default.
- W2753018164 creator A5041531471 @default.
- W2753018164 creator A5045416494 @default.
- W2753018164 creator A5079336692 @default.
- W2753018164 creator A5082271424 @default.
- W2753018164 date "1997-01-01" @default.
- W2753018164 modified "2023-09-26" @default.
- W2753018164 title "MOPP/ABV hybrid treatment for advanced Hodgkin's Disease (HD) and Anaplastic Large Cell Lymphoma (ALCL) : Single institution experience" @default.
- W2753018164 hasPublicationYear "1997" @default.
- W2753018164 type Work @default.
- W2753018164 sameAs 2753018164 @default.
- W2753018164 citedByCount "0" @default.
- W2753018164 crossrefType "journal-article" @default.
- W2753018164 hasAuthorship W2753018164A5021807188 @default.
- W2753018164 hasAuthorship W2753018164A5033103275 @default.
- W2753018164 hasAuthorship W2753018164A5035840054 @default.
- W2753018164 hasAuthorship W2753018164A5038299892 @default.
- W2753018164 hasAuthorship W2753018164A5041531471 @default.
- W2753018164 hasAuthorship W2753018164A5045416494 @default.
- W2753018164 hasAuthorship W2753018164A5079336692 @default.
- W2753018164 hasAuthorship W2753018164A5082271424 @default.
- W2753018164 hasConcept C126322002 @default.
- W2753018164 hasConcept C141071460 @default.
- W2753018164 hasConcept C146357865 @default.
- W2753018164 hasConcept C151730666 @default.
- W2753018164 hasConcept C2776694085 @default.
- W2753018164 hasConcept C2779338263 @default.
- W2753018164 hasConcept C29730261 @default.
- W2753018164 hasConcept C71924100 @default.
- W2753018164 hasConcept C86803240 @default.
- W2753018164 hasConcept C90924648 @default.
- W2753018164 hasConceptScore W2753018164C126322002 @default.
- W2753018164 hasConceptScore W2753018164C141071460 @default.
- W2753018164 hasConceptScore W2753018164C146357865 @default.
- W2753018164 hasConceptScore W2753018164C151730666 @default.
- W2753018164 hasConceptScore W2753018164C2776694085 @default.
- W2753018164 hasConceptScore W2753018164C2779338263 @default.
- W2753018164 hasConceptScore W2753018164C29730261 @default.
- W2753018164 hasConceptScore W2753018164C71924100 @default.
- W2753018164 hasConceptScore W2753018164C86803240 @default.
- W2753018164 hasConceptScore W2753018164C90924648 @default.
- W2753018164 hasLocation W27530181641 @default.
- W2753018164 hasOpenAccess W2753018164 @default.
- W2753018164 hasPrimaryLocation W27530181641 @default.
- W2753018164 hasRelatedWork W1128741287 @default.
- W2753018164 hasRelatedWork W1581869962 @default.
- W2753018164 hasRelatedWork W2021694718 @default.
- W2753018164 hasRelatedWork W2042606748 @default.
- W2753018164 hasRelatedWork W2183352065 @default.
- W2753018164 hasRelatedWork W2330939626 @default.
- W2753018164 hasRelatedWork W2409067283 @default.
- W2753018164 hasRelatedWork W2410978981 @default.
- W2753018164 hasRelatedWork W2415114822 @default.
- W2753018164 hasRelatedWork W2416441974 @default.
- W2753018164 hasRelatedWork W2529118632 @default.
- W2753018164 hasRelatedWork W2533487283 @default.
- W2753018164 hasRelatedWork W2534669560 @default.
- W2753018164 hasRelatedWork W2559909733 @default.
- W2753018164 hasRelatedWork W2561234145 @default.
- W2753018164 hasRelatedWork W2591705641 @default.
- W2753018164 hasRelatedWork W2887768235 @default.
- W2753018164 hasRelatedWork W2979884264 @default.
- W2753018164 hasRelatedWork W2979932463 @default.
- W2753018164 hasRelatedWork W2980789655 @default.
- W2753018164 isParatext "false" @default.
- W2753018164 isRetracted "false" @default.
- W2753018164 magId "2753018164" @default.
- W2753018164 workType "article" @default.